BridgeBio Pharma (BBIO) Debt to Equity (2019 - 2025)
Historic Debt to Equity for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$0.38.
- BridgeBio Pharma's Debt to Equity fell 703.29% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.38, marking a year-over-year decrease of 703.29%. This contributed to the annual value of -$0.5 for FY2024, which is 5268.79% down from last year.
- Per BridgeBio Pharma's latest filing, its Debt to Equity stood at -$0.38 for Q3 2025, which was down 703.29% from -$0.5 recorded in Q4 2024.
- BridgeBio Pharma's Debt to Equity's 5-year high stood at -$0.14 during Q3 2021, with a 5-year trough of -$0.5 in Q4 2024.
- Moreover, its 5-year median value for Debt to Equity was -$0.37 (2023), whereas its average is -$0.36.
- As far as peak fluctuations go, BridgeBio Pharma's Debt to Equity plummeted by 21780.63% in 2021, and later soared by 3022.9% in 2022.
- Over the past 5 years, BridgeBio Pharma's Debt to Equity (Quarter) stood at -$0.5 in 2021, then surged by 30.23% to -$0.35 in 2022, then increased by 4.9% to -$0.33 in 2023, then plummeted by 52.69% to -$0.5 in 2024, then rose by 23.91% to -$0.38 in 2025.
- Its last three reported values are -$0.38 in Q3 2025, -$0.5 for Q4 2024, and -$0.36 during Q3 2024.